Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation.

@article{Larson1982AcuteMS,
  title={Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation.},
  author={Eric B. Larson and Robert C. Roach and Robert Sch{\"o}ne and Thomas F. Hornbein},
  journal={JAMA},
  year={1982},
  volume={248 3},
  pages={328-32}
}
Sixty-four climbers participated in a randomized clinical trial of acetazolamide prophylaxis for acute mountain sickness (AMS) during rapid, active ascent of MT Rainier. Twenty-nine (93.6%) of 31 climbers receiving acetazolamide and 25 (75.8%) of 33 receiving placebo attained the summit. Time spent ascending from sea level to the summit (4,394 m) averaged 33.5 hours (range, 23 to 48 hours). On the summit AMS was less common in climbers receiving acetazolamide, and they experienced less headache… CONTINUE READING
27 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 27 extracted citations

Similar Papers

Loading similar papers…